πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Cyclerion Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Alector, Inc.

Alector, Inc. logo
Market Cap: Medium
Employees: Low

AL001, AL101, AL002, AL003, AL044

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Tags: Alzheimer's, Parkinson's, biopharmaceutical, clinical trials, neurodegeneration, therapies

Symbol: ALEC

Recent Price: $1.72

Industry: Biotechnology

CEO: Dr. Arnon Rosenthal Ph.D.

Sector: Healthcare

Employees: 245

Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 415 231 5660

Leadership

  • Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
  • Marc Grasso, M.D., Chief Financial Officer
  • Gary Romano, M.D., Ph.D., Chief Medical Officer
  • Danielle Pasqualone, Ph.D., J.D., General Counsel
  • Clare Hunt, M.B.A., Chief People Officer
  • Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
  • Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
  • Norah Conway, Senior Vice President, Portfolio and Program Management
  • Neil Berkley, M.S., M.B.A., Chief Business Officer
  • Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
  • Elizabeth Garofalo, M.D., Board Member
  • Paula Hammond, Ph.D., Board Member
  • Richard H. Scheller, Ph.D., Board Member
  • David Wehner, Board Member
  • Kristine Yaffe, M.D., Board Member
  • Errol De Souza, Ph.D., Board Member
  • Mark Altmeyer, M.B.A., Board Member

Last updated: 2024-12-31

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Athira Pharma, Inc.

Athira Pharma, Inc. logo
Market Cap: Lowest
Employees: Low

ATH-1017

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.

Tags: Alzheimer's disease, Parkinson's disease, biopharmaceutical, clinical trials, neurodegeneration

Symbol: ATHA

Recent Price: $0.55

Industry: Biotechnology

CEO: Dr. Mark J. Litton M.B.A., Ph.D.

Sector: Healthcare

Employees: 65

Address: 18706 North Creek Parkway, Bothell, WA 98011

Phone: 425 620 8501

Last updated: 2024-12-31

CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Berubicin

CNS Pharmaceuticals, Inc. is a clinical pharmaceutical company focused on developing anti-cancer drugs for brain and central nervous system tumors. Their lead drug candidate, Berubicin, targets glioblastoma multiforme through clinical trials and partnerships with notable institutions.

Tags: Anti-cancer drugs, Berubicin, Brain Tumors, CNS Tumors, Clinical Trials, Pharmaceuticals

Symbol: CNSP

Recent Price: $0.11

Industry: Biotechnology

CEO: Mr. John Michael Climaco Esq., J.D.

Sector: Healthcare

Employees: 3

Address: 2100 West Loop South, Houston, TX 77027

Phone: 800 946 9185

Last updated: 2024-12-31

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CY6463

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.

Tags: CNS diseases, CY6463, biopharmaceutical, clinical-stage, therapy development

Symbol: CYCN

Recent Price: $3.45

Industry: Biotechnology

CEO: Dr. Regina Graul Ph.D.

Sector: Healthcare

Employees: 1

Address: 245 First Street, Cambridge, MA 02142

Phone: 857 327 8778

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALRN-6924

Aileron Therapeutics, Inc. is a clinical stage oncology company developing ALRN-6924 for various cancer treatments, with multiple clinical trials in progress.

Tags: ALRN-6924, cancer therapies, chemoprotection, clinical stage, clinical trials, oncology

Symbol: ALRN

Recent Price: $2.32

Industry: Biotechnology

CEO: Dr. James Brian Windsor Ph.D.

Sector: Healthcare

Employees: 15

Address: 285 Summer Street, Boston, MA 02210

Phone: 617 995 0900

Last updated: 2024-12-31

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Medium

AMX0035

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their leading product, AMX0035, is aimed at ALS treatment.

Tags: ALS, AMX0035, biopharmaceutical, neurodegenerative diseases, therapeutics

Symbol: AMLX

Recent Price: $3.84

Industry: Biotechnology

CEO: Mr. Joshua B. Cohen

Sector: Healthcare

Employees: 384

Address: 43 Thorndike Street, Cambridge, MA 02141

Phone: 617 682 0917

Leadership

  • Linda A. Arsenault, Chief Human Resources Officer
  • Camille L. Bedrosian, MD, Chief Medical Officer
  • Josh Cohen, Co-CEO & Co-Founder
  • James M. Frates, Chief Financial Officer
  • Tom Holmes, Chief Technical Operations Officer
  • Justin Klee, Co-CEO & Co-Founder
  • Gina M. Mazzariello, Chief Legal Officer & General Counsel
  • Rudolph Tanzi, PhD, Founding Chair of the Amylyx SAB
  • Wally Gilbert, Special Advisor
  • Kari Firestone, Director
  • Paul Fonteyne, Director
  • George Milne, Chairman
  • Daphne Quimi, Director
  • Bernhardt G. Zeiher, MD, FACP, FCCP, Director

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CT1812

Cognition Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Its lead product, CT1812, is designed to treat Alzheimer's disease and dementia with Lewy bodies.

Tags: Alzheimer's disease, biopharmaceutical, central nervous system, retina disorders, small molecule therapeutics

Symbol: CGTX

Recent Price: $0.75

Industry: Biotechnology

CEO: Ms. Lisa Ricciardi

Sector: Healthcare

Employees: 25

Address: 2500 Westchester Avenue, Purchase, NY 10577

Phone: 412 481 2210

Leadership

  • Lisa Ricciardi, Chief Executive Officer​
  • Anthony C. Caggiano, M.D., Ph.D., Chief Medical Officer, Head of R&D
  • John Doyle, Chief Financial Officer
  • Anita Cornet, Head of Quality
  • Theresa Devins, DrPH, Vice President, Clinical Operations
  • Mary Hamby, Ph.D., Vice President, Research
  • Bobby Horn, Corporate Controller
  • Jennifer Iaci, Vice President, Development Operations
  • Steven A. Weissman, Ph.D., Vice President and Head of CMC
  • Jack A. Khattar, CEO
  • Aaron Fletcher, Ph.D.,
  • Brett P. Monia, Ph.D., CEO
  • Ellen B. Richstone,
  • Peggy Wallace,

Last updated: 2024-12-31

Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Trappsol Cyclo

Cyclo Therapeutics, Inc. is a clinical stage biotechnology company focused on developing cyclodextrin-based products for various diseases, with its lead drug candidate Trappsol Cyclo undergoing Phase III trials for Niemann-Pick Type C disease and exploration for Alzheimer's treatment.

Tags: Alzheimer's disease, Niemann-Pick Type C, biotechnology, cyclodextrin-based products, pharmaceuticals

Symbol: CYTH

Recent Price: $0.60

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. N. Scott Fine

Sector: Healthcare

Employees: 8

Address: 6714 NW 16th Street, Gainesville, FL 32653

Phone: 386 418 8060

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

RLY-4008, RLY-2608, RLY-1971

Relay Therapeutics, Inc. is a clinical-stage company that focuses on precision medicine in oncology and genetic diseases by transforming the drug discovery process. Their leading products include small molecule inhibitors for advanced cancer treatment.

Tags: FGFR2, PI3Ka, Src homology, clinical-stage, drug discovery, genetic diseases, oncology, precision medicines, small molecule inhibitors

Symbol: RLAY

Recent Price: $4.18

Industry: Biotechnology

CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 323

Address: 399 Binney Street, Cambridge, MA 02139

Phone: 617 370 8837

Last updated: 2024-12-31

Rallybio Corporation

Rallybio Corporation logo
Market Cap: Lowest
Employees: Lowest

RLYB212

Rallybio Corporation is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and delivering therapies for severe and rare diseases, with a lead product candidate RLYB212 in clinical trials.

Tags: biotechnology, clinical trials, monoclonal antibodies, rare diseases, therapeutics

Symbol: RLYB

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Stephen Uden M.B, M.D.

Sector: Healthcare

Employees: 25

Address: 234 Church Street, New Haven, CT 06510

Phone: 203 859 3820

Last updated: 2024-12-31

Synaptogenix, Inc.

Synaptogenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

Bryostatin-1

Synaptogenix, Inc. is a biopharmaceutical company focused on developing drug candidates for neurodegenerative diseases, including Alzheimer's disease, using Bryostatin-1.

Tags: Alzheimer's disease, Bryostatin-1, biopharmaceutical, clinical development, neurodegenerative diseases

Symbol: SNPX

Recent Price: $3.37

Industry: Biotechnology

CEO: Dr. Alan J. Tuchman M.D., MBA(FAAN)

Sector: Healthcare

Employees: 5

Address: 1185 Avenue of the Americas, New York, NY 10036

Phone: 973 242 0005

Last updated: 2024-12-31

Theriva Biologics, Inc.

Theriva Biologics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SYN-004, SYN-020, VCN-01

Theriva Biologics Inc. is a clinical-stage company developing therapeutics to address diseases with high unmet needs, including SYN-004 for preventing microbiome damage and SYN-020 for treating GI and systemic diseases.

Tags: biologics, biopharmaceutical, clinical-stage, disease treatment, microbiome, therapeutics

Symbol: TOVX

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Steven A. Shallcross CPA

Sector: Healthcare

Employees: 22

Address: 9605 Medical Center Drive, Rockville, MD 20850

Phone: 301 417 4364

Last updated: 2024-12-31

Denali Therapeutics Inc.

Denali Therapeutics Inc. logo
Market Cap: High
Employees: Medium

BIIB122/DNL151

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.

Tags: ALS, Alzheimer's disease, Parkinson's disease, biopharmaceutical, hunter syndrome, multiple sclerosis, neurodegenerative diseases

Symbol: DNLI

Recent Price: $20.24

Industry: Biotechnology

CEO: Dr. Ryan J. Watts Ph.D.

Sector: Healthcare

Employees: 364

Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 866 8548

Last updated: 2024-12-31

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Medium

RNA-targeted therapeutics

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.

Tags: ALS, Biotechnology, Pharmaceuticals, RNA therapeutics, SPINRAZA, TEGSEDI, TTR amyloidosis, WAYLIVRA

Symbol: IONS

Recent Price: $34.92

Industry: Biotechnology

CEO: Dr. Brett P. Monia Ph.D.

Sector: Healthcare

Employees: 927

Address: 2855 Gazelle Court, Carlsbad, CA 92010

Phone: 760 931 9200

Last updated: 2024-12-31